Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity
Article meta
Article Date: 25 March 2026
Article URL: https://www.nature.com/articles/s41586-026-10278-0
Article Title: Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity
Article Image: Nature (article page)
Summary
This study defines how tumours that aberrantly express neuronal N-methyl-D-aspartate receptors (NMDARs) recruit pre-existing, germline-configuration B cells and drive affinity maturation to produce high-affinity anti-NMDAR IgG. Using an inducible mouse TNBC (4T1) model expressing GluN1–GluN2B, the authors show that ectopic NMDAR expression triggers tertiary lymphoid structures, class switching and production of antibodies that can both constrain tumour growth and, if they access the CNS, cause features of anti-NMDAR encephalitis (ANRE).
Key methods: spatial and single-cell RNA-seq, single-cell BCR sequencing and phylogenies, recombinant monoclonal antibody expression, cryo-electron microscopy (cryo-EM) of antibody–NMDAR complexes, electrophysiology (TEVC), passive antibody transfer into mouse ventricles, metabolic/behavioural monitoring and analysis of a 53-patient TNBC plasma/tissue cohort.
Key Points
- Cancer cells in a subset of human triple-negative breast cancers (TNBC) express canonical GluN1–GluN2B NMDARs (validated by spatial transcriptomics, IF and flow cytometry).
- Ectopic NMDAR expression in an immunocompetent, DOX-inducible 4T1 TNBC mouse model provokes strong adaptive responses: peritumoural tertiary lymphoid structures, B- and T-cell recruitment and rapid anti-NMDAR IgG production.
- Single-cell BCR sequencing traced affinity-matured intratumoural clonotypes back to germline-configuration naive B cells from tumour-draining lymph nodes, proving recruitment of pre-existing low-affinity autoreactive B cells.
- Cryo-EM shows tumour-derived antibodies converge on the NMDAR amino-terminal domain (ATD); affinity maturation increases the interaction surface and affinity (KD from ~400–7,700 nM germline to ~6–263 nM matured).
- Antibodies vary functionally: some potentiate NMDAR currents (causing excitotoxicity and tumour cytotoxicity), others inhibit or are neutral; structural α4′–α5 distance in ATD predicts functional effect.
- Passive intracerebroventricular transfer of a potentiating monoclonal antibody (SK3D) produced ANRE-like features in mice — hyperthermia, raised energy expenditure and a lower seizure threshold — whereas inhibitory antibodies did not.
- In a cohort of 53 TNBC patients, 15% had elevated plasma anti-NMDAR IgG; these antibody-high patients showed no disease progression over median 4.3 years, linking humoral anti-NMDAR immunity with improved tumour control.
- Overall conclusion: ectopic onconeural antigen expression can unmask germline-encoded autoreactive B cells, producing antibodies that are both antitumour and potentially neurotoxic if they cross a disrupted blood–brain barrier.
Content summary
The authors first reanalysed public breast cancer datasets and used spatial RNA profiling and immunofluorescence to confirm GluN1/GluN2B expression in a minority of TNBC tumour cells. They generated a 4T1 cell line with DOX-inducible GluN1–GluN2B and implanted these cells into immunocompetent female BALB/c mice. DOX induction produced robust intratumoural immune activation, tertiary lymphoid structures and rapid rises in plasma anti-NMDAR titres; in mice with high titres, spontaneous tumour regression occurred.
Single-cell B cell sequencing with antigen capture allowed cloning of multiple NMDAR-binding clonotypes. Phylogenetic reconstruction showed somatic hypermutation and class switching in tumours, and imputed/unmutated germline precursors — directly demonstrating that unmutated B cells with low baseline NMDAR affinity seed the response and undergo affinity maturation in situ.
Cryo-EM structures of germline and matured antibodies bound to GluN1–GluN2B revealed epitope convergence on the ATD and clarified how somatic changes increase affinity and alter receptor conformation. Electrophysiology in Xenopus oocytes showed antibody-specific modulation: potentiation or inhibition of agonist-induced currents, which correlated with structural measures. Potentiating antibodies were cytotoxic to NMDAR-expressing tumour cells in vitro and, when administered as purified IgG in B-cell-deficient tumour-bearing mice, induced tumour regression. Intracerebroventricular infusion of a potentiating antibody produced thermoregulatory and seizure phenotypes reminiscent of ANRE.
Human relevance: among 53 TNBC patients, 8 (15%) had plasma anti-NMDAR titres above the 95% upper limit; tumours from antibody-high patients showed epithelial NMDAR expression. Antibody presence correlated with favourable clinical outcomes in this small cohort.
Context and relevance
Why this matters: the paper links paraneoplastic autoimmunity mechanistically to ectopic tumour expression of normally immune-privileged antigens and to recruitment of germline B cells. It explains a double-edged phenomenon in oncology: autoantibodies that help suppress tumours can, if they access the CNS, cause debilitating neuropsychiatric disease. This is directly relevant for clinicians and researchers working on cancer immunotherapy, paraneoplastic syndromes, antibody-mediated encephalitis and B-cell biology.
Why should I read this?
Quick and blunt: if you care about why some cancers disappear when patients get autoimmune encephalitis — or why checkpoint inhibitors sometimes cause neurotoxicity — this paper gives the mechanism. It shows tumours can switch on a brain protein, wake up pre-existing B cells, and generate antibodies that both fight the tumour and, if the blood–brain barrier breaks, wreck brain function. Saves you digging through dense methods: cryo-EM, single-cell BCR phylogenies and mouse transfer studies all point to one unified model.
Author style
Punchy: the authors present a tight, multi-modal story that connects molecular structure to mouse pathology and human samples. This is significant — it reframes paraneoplastic autoimmunity not as a curiosity but as an intrinsic by-product of immune surveillance that has predictable molecular and functional signatures. For immuno-oncology and neuroimmunology, that is big: it suggests routes to preserve anti-tumour benefit while minimising neurotoxicity.
Implications
- Therapeutic: potential to design strategies that keep the antitumour antibody response while preventing CNS access or selectively neutralising NMDAR-potentiating clones.
- Diagnostic: screening for anti-NMDAR antibodies in patients with NMDAR-positive tumours could identify those with better prognosis or risk for paraneoplastic encephalitis.
- Scientific: supports the hypothesis that germline-encoded autoreactive B cells exist to sense altered cellular states and can be co-opted during cancer.